Articles related to NURSING

HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.

According to a University of Washington research, only 40% of rural counties nationally had at least one licensed physician who could prescribe buprenorphine in 2016. The analysis discovered that by 2020, that number had increased to 63%. The increase was attributed by the study to modifications in federal regulations that permit NPs, PAs, and other healthcare professionals to prescribe buprenorphine. Only doctors could perform this in the past, and many remote counties lacked any. In 2002, Suboxone received approval from federal regulators, providing a new option for addiction treatment in communities without methadone facilities. Marshalltown, a town of 27,000 people encircled by rural areas, offers a feasible alternative, according to Andrea Storjohann, NP.

Medical oncologists, pulmonologists, pathologists, oncology nurses, pharmacists, and other oncology HCPs who treat patients with lung cancer should be better able to describe ideal evidence-based treatment selection and sequencing recommendations for the use of immuno-oncologic therapy in patients with early-stage NSCLC and evaluate clinical trial data of emerging immunotherapy-based agents in the treatment after completing this three-chapter, 0.50-credit CME activity.

A reflective case study highlights this author’s take on papillary thyroid cancer, which has high survivability but cannot be considered “good.” Telling patients they have good cancer is dismissive and minimizes the patient experience associated with this diagnosis. When caring for patients with papillary thyroid cancer, this commonly used statement is contradictory. Providers of all specialties must consider the psychological and physiological effects that papillary thyroid cancer has on patients. It is critical to practice improving news delivery through effective and empathetic communication.

“The perfect storm of lazy MDs, an incompetent ASA and the dramatic taming of the traditionally wild surgical procedures and advances in anesthesia have set up the perfect stage for the aggressive takeover of the specialty by the nursing realm, where it all started in the first space. Today’s MD anesthesiologists have ceded control of the specialty and are rightly a footnote in history—not ‘misunderstood’ at all, as Dr. Sherer would have us believe.”

This overview and discussion highlights the learnings gleaned during practice in a ketamine service unit. Discussion points include treatment considerations for the two entities, switching from IV to intranasal, and a collection of pearls.